{"id":5700,"date":"2019-11-18T13:56:00","date_gmt":"2019-11-18T13:56:00","guid":{"rendered":"http:\/\/www.library.sath.nhs.uk\/research\/?p=5700"},"modified":"2021-03-22T09:57:33","modified_gmt":"2021-03-22T09:57:33","slug":"patients-and-partners-views-of-care-and-treatment-provided-for-metastatic-castrate%e2%80%90resistant-prostate-cancer-in-the-uk-2019","status":"publish","type":"post","link":"https:\/\/www.library.sath.nhs.uk\/research\/2019\/11\/18\/patients-and-partners-views-of-care-and-treatment-provided-for-metastatic-castrate%e2%80%90resistant-prostate-cancer-in-the-uk-2019\/","title":{"rendered":"Patients\u2019 and partners\u2019 views of care and treatment provided for metastatic castrate\u2010resistant prostate cancer in the UK (2019)"},"content":{"rendered":"<p><strong>Type of publication:<\/strong><br \/>\nJournal article<\/p>\n<p><strong>Author(s):<\/strong><br \/>\nCatt S, Matthews L, May S, Payne H, Mason M, Jenkins V.<\/p>\n<p><strong>Citation:<\/strong><br \/>\nEuropean Journal of Cancer Care. 2019 Nov;28(6):e13140.<\/p>\n<p><strong>Note:<\/strong><br \/>\n14 of the 37 participants were recruited from the Royal Shrewsbury Hospital<\/p>\n<p><strong>Abstract:<\/strong><br \/>\nOBJECTIVE: Documentations of the experiences of patients with advanced prostate cancer and their partners are sparse. Views of care and treatment received for metastatic castrate-resistant prostate cancer (mCRPC) are presented here.<br \/>\nMETHODS: Structured interviews conducted within 14 days of a systemic therapy for mCRPC starting and 3 months later explored the following: treatment decisions, information provision, perceived benefits and harms of treatment, and effects of these on patients' and partners' lives.<br \/>\nRESULTS: Thirty-seven patients and 33 partners recruited from UK cancer centres participated. The majority of patients (46%) reported pain was their worst symptom and many wanted to discuss its management (baseline-50%; 3 months-33%). Patients and partners believed treatment would delay progression (&gt;75%), improve wellbeing (33%), alleviate pain (\u224812%) and extend life (15% patients, 36% partners). At 3 months, most men (42%) said fatigue was the worst treatment-related side effect (SE), 27% experienced unexpected SEs and 54% needed help with SEs. Most patients received SE information (85% written; 75% verbally); many additionally searched the Internet (33% patients; 55% partners). Only 54% of patients said nurse support was accessible.<br \/>\nCONCLUSION: Pain and other symptom management are not optimal. Increased specialist nurse provision and earlier palliative care links are needed. Dedicated clinics may be justified.<\/p>\n<p><a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/ecc.13140\" target=\"_blank\" rel=\"noopener noreferrer\">Link to full-text<\/a><\/p>\n<p><strong>Altmetrics:<\/strong><\/p>\n<div class=\"altmetric-embed\" data-badge-details=\"right\" data-badge-type=\"medium-donut\" data-pmid=\"31475410\" data-hide-no-mentions=\"true\"><\/div>\n<p><script type='text\/javascript' src='https:\/\/d1bxh8uas1mnw7.cloudfront.net\/assets\/embed.js'><\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Type of publication: Journal article Author(s): Catt S, Matthews L, May S, Payne H, Mason M, Jenkins V. Citation: European Journal of Cancer Care. 2019 Nov;28(6):e13140. Note: 14 of the 37 participants were recruited from the Royal Shrewsbury Hospital Abstract:<span class=\"ellipsis\">&hellip;<\/span><\/p>\n<div class=\"read-more\"><a href=\"https:\/\/www.library.sath.nhs.uk\/research\/2019\/11\/18\/patients-and-partners-views-of-care-and-treatment-provided-for-metastatic-castrate%e2%80%90resistant-prostate-cancer-in-the-uk-2019\/\">Read more <span class=\"screen-reader-text\">Patients\u2019 and partners\u2019 views of care and treatment provided for metastatic castrate\u2010resistant prostate cancer in the UK (2019)<\/span><span class=\"meta-nav\"> &#8250;<\/span><\/a><\/div>\n<p><!-- end of .read-more --><\/p>\n","protected":false},"author":12,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[200],"tags":[832,255,353,646],"class_list":["post-5700","post","type-post","status-publish","format-standard","hentry","category-staff-publication","tag-832","tag-cancer","tag-oncology","tag-prostate-cancer"],"_links":{"self":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/5700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/comments?post=5700"}],"version-history":[{"count":2,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/5700\/revisions"}],"predecessor-version":[{"id":5702,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/5700\/revisions\/5702"}],"wp:attachment":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/media?parent=5700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/categories?post=5700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/tags?post=5700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}